Other languages Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
2.17 ^USD	-3.56%		-11.07%	+11.86%

03-04	North American Morning Briefing : Stock Futures -2-	DJ
02-28	Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	02-13
MaxCyte's strategic platform licences redeem otherwise modest results	01-09
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
Lyell Immunopharma, Inc. Presents New Nonclinical Data at 38th Annual Meeting of SITC on Innovations Designed to Shorten Tumor Infiltrating Lymphocyte Manufacturing, LYL119 as Well as Data on New Technologies and Design of its Two Clinical Trials in Progress	23-10-31
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's Car T-Cell Therapy on Cellares' Cell Shuttle Platform	23-09-11
Insider Sell: Lyell Immunopharma	23-08-17
Lyell Immunopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
MaxCyte Signs Strategic Platform License with Lyell Immunopharma	23-07-06
MaxCyte inks strategic platform license with Lyell Immunopharma	23-07-06
Lyell Immunopharma, Inc. Appoints Matthew Lang as Chief Business Officer	23-07-05
Lyell Immunopharma, Inc. Announce Resignation of Rahsaan Thompson as the Chief Legal Officer	23-06-06
Lyell Immunopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28
Lyell Immunopharma, Inc. Appoints Lynn Seely as CEO	22-12-15
Lyell Immunopharma, Inc. Appoints Lynn Seely as President	22-12-15
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors	22-11-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Other languages

Filters